
News|Articles|October 1, 2006
High-dose statin therapy displays benefit in preventing cardiovascular events compared with standard doses
Intensive lipid lowering with high-dose 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) provides a significant benefit over standard-dose statin therapy in preventing nonfatal cardiovascular outcomes and also may reduce the incidence of cardiovascular death, according to results of a meta-analysis published in the Journal of the American College of Cardiology.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma
3
New study confirms benefits of GLP-1 drugs in patients with PAD
4
Key Takeaways, Study Limitations, and the Broader Implications of CROWN for Patients, Providers, and Payers
5
































